Vadodara, 23 June, 2020
Vadodara’s Pharma Industries continued during the lockdown. The country produced the most vitamin-C and paracetamol drugs. Also a pharma company of Padra made indigenous KSM i.e. HNDA and 4,7, DCQ for making hydroxychloroquine. Earlier this key had to depend on China for starting material. Had to be imported from China. The industry gained momentum as its local alternative became available.
The pharma sector units were allowed to continue by Collector Shalini Agarwal. Medicines including Vitamin-C Paracetamol manufactured from Vadodara could also be exported. Compared to April-May last year, the pharma sector in Vadodara has seen a significant increase in production this year.
Vadodara is emerging as a hub of pharma industries across the country. There are 325 units in the city and district for medicines, medical equipment, food supplements, AYUSH related products. 45 thousand people work. The goods produced here are also exported to countries in Latin America, Africa, and Europe.
This is reflected in the fact that in the last two years, Gujarat FDCA has shown green light for building 214 new plants, both greenfield and brownfield, for manufacture of pharmaceutical products Of this, as many as 60-70 plants have gone into production. New licences have been granted to as many as 150 entities for contract manufacturing in the state.In the past one decade, Gujarat pharma production had hit the low of 25% share in the pharma market and also bounced back to 33%. The exodus back then had brought Gujarat’s share in India’s pharma production from peak 42% to less than 25%.The share, industry players estimate, is expected to rise to 40-42% over the coming years.
According to the ASSOCHAM recent paper on “Generic Drug, Clinical Trials & Technology” highlights that Gujarat’s contribution in the growth of India’s pharmaceutical industry has been significant. The Gujarat’s share in total exports grew from eight percent in 2002-03 to 22 percent. Bulk drugs constituted 40 percent while formulations accounted for 60 percent of the total exports whereas the state has successfully captured a share of over 42 percent of India’s total turnover, highlights the ASSOCHAM paper.
The paper further reveals that nearly 52,000 people are employed in Gujarat’s pharmaceutical sector, which has witnessed 54% compound annual growth rate (CAGR) in capital investments over the last three years. There are currently 3,500 drug manufacturing units in Gujarat. The state houses several established companies such as Torrent Pharma, Zydus Cadila, Alembic, Sun Pharma, Claris, Intas Pharmaceuticals which have operations in the world’s major pharma markets.
provide direct and indirect employment to 3-4 lakh individuals. The new plants will provide employment — directly and indirectly — to an additional 1 lakh people.
Gujarat has about one-third share in India’s Rs 2.64 lakh crore pharma market. Total Pharmaceuticals 2015-16 29.3-40.1 (USD billion) in India.
When tested for quality, drugs produced in Gujarat have failure ratio of 1.69%, while the national average for the same is 4-5%. Our quality is much higher than other states.
Gujarat, which accounts for 28% of the country’s exports, has a large number of pharmacy colleges and institutions, research and development (R&D) centres, contract research firms and allied industries. About 40% of machineries required for a pharma plant are made by units located in Ahmedabad alone.
3574 Manufacturing licenses in Gujarat
78% of India’s cardiac stents are anufactured in Gujarat
60% India’s orthopaedic implants are manufactured in Gujarat
Only manufacturer of Dapsone in India
50% of India’s intraocular lenses are manufactured in Gujarat
80% World’s Isoniazid is produced in Gujarat
1st Diagnostic reagent manufacturer in India to obtain product prequalification from WHO Geneva, is located in Gujarat
Turnover of Gujarat Pharmaceutical industry was worth ~USD 6.7 Billion in
2015-16; while exports was worth ~USD 3.06 Billion
• Provides employment to around 85,000 people
•More than 255 WHO-GMP compliant manufacturing facilities in India are from
• Accounts for 53% of the total medical devices manufacturers in the country
• World’s leading companies entrust contract manufacturing work to Gujarat
Gujarat is hub approx. 40% of Contract Research Organizations (CROs) in the country. Its well established healthcare sector, strong infrastructure facilities and relatively low real estate costs has lured many global and local CROs to set up shop in the state.
There is also a strong local and global opportunity for Gujarat in the manufacturing of pharmaceutical machinery, given its strong and well established engineering sector. According to industry estimates, approximately 35-40 percent of India’s pharmaceutical machinery is produced in Gujarat.
The value of the global pharmaceutical market expected to grow by 7–8% in 2014 to US$ 900 billion, compared with a 4–5% pace in 2010. The Indian pharmaceutical industry is growing at an annual rate of 11 % while the clinical research industry is growing at an annual rate of 84%.
According to ASSOCHAM analysis 2014, the current clinical research industries of Rs 8,000 crore may touch $1.5bn ($1500m) and generate 50,000 professionals employment in the next five years.
Market value for clinical trials outsourced to India is estimated at around $300 million, increased by 65% in 2006, it is expected to touch $1.5-2.5 billion by 2014. By 2014, the industry will spend USD 450M on clinical trials in India.